Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma

Part of paid clinical trials in La Jolla, California.

Sponsor
University of California, San Diego
Study ID
NCT03590652
Phase
PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to determine the overall response rate of patients with Multiple Myeloma to the combination of Daratumumab, Ixazomib, Pomalidomide and Dexamethasone.

Key Dates

Start date
Oct 17, 2018
Status verified
Oct 2025
Primary completion
Jul 2, 2025
Completion
Jul 2, 2025

Study Design

Enrollment
23 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: ixazomib, daratumumab, pomalidomide and dexamethasone
    Daratumumab will be administered at 16mg/kg IV weekly x 8 weeks, biweekly x 8 weeks, then monthly. Pomalidomide 4mg will be administered orally daily for days 1-21. Patients ≤ age 75 will receive a 40mg dose of dexamethasone, and those over the age of 75 may receive a 20mg dose of dexamethasone orally on days 1, 8, 15, and 22 (weekly). Ixazomib will be administered 4mg orally on days 1, 8 and 15.

Primary Outcome Measure

Overall Response Rate [ Time Frame: 2 years ]

Locations (4)

FacilityCityStateZIPSite coordinators
UCSD Moores Cancer CenterLa JollaCalifornia92093-
University of California, Los AngelesLos AngelesCalifornia90024-
University of California, DavisSacramentoCalifornia95817-
University of California, San FranciscoSan FranciscoCalifornia94115-

Find similar trials in La Jolla, CA

By condition
Multiple myeloma
By specialty
OncologyBlood cancer
By research site
UCSD Moores Cancer Center· La Jolla, CAUniversity of California, Los Angeles· Los Angeles, CAUniversity of California, Davis· Sacramento, CAUniversity of California, San Francisco· San Francisco, CA

Related Studies